Single Versus Combined Antibiotic Therapy for Bacterial Peritonitis in CAPD Patients
NCT ID: NCT01785641
Last Updated: 2024-02-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
300 participants
INTERVENTIONAL
2012-12-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Pharmacokinetic Study of Ceftazidime and Cefazolin
NCT04367974
PDRI Rates Among CAPD Patients at a Tertiary University Hospital: A 5-Year Retrospective Study
NCT04950179
The Efficacy of Prolonged Antibiotic Therapy for the Prevention of Relapsing Peritonitis in Peritoneal Dialysis Patients With High Dialysis Effluent Bacterial DNA Fragment Levels
NCT02593201
Peritonitis Prevention After Insertion of Peritoneal Dialysis Catheter.
NCT03046511
A Pharmacokinetic Study of Cefepime After Administration Into Dialysate in Patients With Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis
NCT00497744
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ceftazidime+ciprofloxacin
2 synergistic antibiotics(ceftazidime IP and ciprofloxacin po for gram negative bacterial peritonitis)
ceftazidime+ciprofloxacin
2 synergistic antibiotics: ceftazidime IP + ciprofloxacin po for gram negative bacterial peritonitis
ceftazidime monotherapy
ceftazidime IP for gram negative bacterial peritonitis
ceftazidime monotherapy
ceftazidime IP for gram negative bacterial peritonitis
cefazolin+gentamicin
cefazolin IP and gentamicin IP for gram positive bacterial peritonitis
cefazolin+gentamicin
cefazolin IP + gentamicin IP for gram positive bacterial peritonitis
cefazolin monotherapy
cefazolin IP for gram positive bacterial peritonitis
cefazolin monotherapy
cefazolin IP for gram positive bacterial peritonitis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ceftazidime+ciprofloxacin
2 synergistic antibiotics: ceftazidime IP + ciprofloxacin po for gram negative bacterial peritonitis
ceftazidime monotherapy
ceftazidime IP for gram negative bacterial peritonitis
cefazolin+gentamicin
cefazolin IP + gentamicin IP for gram positive bacterial peritonitis
cefazolin monotherapy
cefazolin IP for gram positive bacterial peritonitis
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ESRD patients on continuous ambulatory peritoneal dialysis more than 4 weeks
* presence of symptom or sign of peritonitis
* presence of WBC \>100cell/mm3 with PMN \>50% in peritoneal dialysate or gram stain positive for gram positive or gram negative bacteria
Exclusion Criteria
* peritonitis from the organisms that required combined antibiotic therapy according to ISPD guideline 2010
* hospital-acquired peritonitis
* presence of catheter-related infection
* history of peritonitis within 4 weeks
* currently taking antibiotic
* allergic to the antibiotic that used in the study(penicillin or cephalosporin or quinolone or aminoglycoside)
15 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chulalongkorn University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nalinee Saiprasertkit, MD.
Role: PRINCIPAL_INVESTIGATOR
Chulalongkorn University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chulalongkorn university
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RA56/006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.